Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptorToshio Nishimura(Gunma University), Takashi Minegishi(Gunma University)BMC CancerDecember 1, 201510.1186/s12885-015-1975-5Cited by 21SaveCiteExport RISWatch citationsRelated PapersPredictive and prognostic role of activated mammalian target of rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy|Oncology Reports|2006|57